Bold claim: a diabetes and weight-loss drug ingredient may also curb alcohol use. And this is where the story gets even more intriguing... new research shows tirzepatide—the active component in Mounjaro—can decrease alcohol intake and relapse-like behaviors in rodents, offering a potential new angle in the search for alcohol use disorder treatments.
Researchers at the University of Gothenburg built on prior work with semaglutide, the active ingredient in Ozempic and Wegovy, which was shown to reduce alcohol consumption in rats. The current study, published in eBioMedicine, centers on tirzepatide and its effects.
In treated animals, voluntary alcohol consumption dropped by more than 50%. The drug also prevented relapse-like drinking: after a break from alcohol, the animals did not rebound to previous levels; they drank less than before. The observed reductions were robust across long-term consumption, binge-like drinking, and relapse-like drinking, in both male and female subjects.
A particularly compelling aspect is the study’s insight into how this drug class might influence the brain’s reward system. The team identified that tirzepatide dampened alcohol-induced changes in dopamine, a key neurotransmitter driving the brain’s reward pathways. This effect seemed to involve the lateral septum, a brain region associated with motivation, reward, and relapse in both animals and humans, offering a potential neurobiological explanation for why similar medications can lessen alcohol craving and intake.
The researchers also noted changes in histone-related proteins in the lateral septum, which can influence gene activation. These alterations have been linked to substance use and addiction in prior work. However, the study does not prove that these histone changes cause the reduction in drinking. Instead, they may be part of the broader biological mechanisms affected by tirzepatide.
Collaborative effort details
The study was conducted by scientists at the University of Gothenburg and the Medical University of South Carolina. It combined behavioral assessments with measurements of brain neurotransmitters and molecular analyses to provide a comprehensive picture.
Though these findings do not establish tirzepatide as a new treatment for alcohol use disorder, they strengthen the idea that therapies targeting the brain’s reward and metabolic signaling systems could be worthy of further exploration as potential options.
Quotable perspective
Elisabet Jerlhag Holm, Professor of Pharmacology at the Sahlgrenska Academy, notes that while this is not a new approved therapy yet, the results support ongoing investigation into how these neural systems could be leveraged for future treatments.
Source details
Edvardsson, C. E., et al. (2026). Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents. eBioMedicine. DOI: 10.1016/j.ebiom.2025.106119.https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(25)00569-9/fulltext
Discussion points
- The study suggests a neurobiological mechanism involving dopamine signaling and the lateral septum that could help explain reduced drinking with tirzepatide.
- Histone-related protein changes were observed, but causality remains unproven. Could these epigenetic shifts contribute to longer-term changes in alcohol-related behavior?
- How might dual GIP/GLP-1 receptor agonists compare with single-target therapies in addressing alcohol use disorder in humans?
What do you think about the potential of metabolic-receptor drugs in treating addiction? Would you like to see further research translated into human trials, or do you harbor concerns about side effects or applicability across diverse populations?
